| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 70,047 | |||
| General and administrative | 17,290 | |||
| Total operating expenses | 87,337 | |||
| Loss from operations | -87,337 | |||
| Interest income (expense), net | 4,380 | |||
| Other income (expense), net | -1 | |||
| Net loss and comprehensive loss | -82,958 | |||
| Net loss attributable to common stockholders | -82,958 | |||
| Basic EPS | -2.46 | |||
| Diluted EPS | -2.46 | |||
| Basic Average Shares | 33,700,550 | |||
| Diluted Average Shares | 33,700,550 | |||
Eikon Therapeutics, Inc. (EIKN)
Eikon Therapeutics, Inc. (EIKN)